Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Eric Jeffrey Topol · SCRIPPS RESEARCH INSTITUTE, THE · 2023 · $6,029,792 — PROJECT SUMMARY / ABSTRACT The Scripps Research Translational Institute (SRTI) is the foundation for the Scripps hub and is dedicated to accelerating science that will improve human health. SRTI’s emphasis on genomics, digital medicine, and informatics/analytics fosters a multi-dimensional understan…
Heinrich Feldmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $2,585,920 — Since February 2020 we have been mainly working on COVID projects. We have established the Syrian hamster disease model for pathogenesis studies and countermeasure development (Rosenke et al., manuscript in preparation). We have established an in vitro drug screening pipeline that will feed promisin…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $67,461 — The project has yielded the following results: 1. Synthesis of tail-modified SARS-CoV2 envelope spike (S) mRNAs to facilitate VLP formation with lentivirus core proteins. In order to facilitate the assembly of VLPs containing lentivirus (HIV-1 or SIV) core proteins, we have designed S proteins modif…
William Elkins · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $57,413 — MGGM initiated several collaborative projects for creating genetically engineered animal models for understanding the mechanisms of novel SARS-CoV2 virus transmission and therapeutic targets. Novel corona virus SARS-CoV2 is responsible for the COVID-19. Angiotensin Converting Enzyme 2 (ACE2), the r…
Donald Lo · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2020 · $1,991,523 — TDB scientists have extensive experience in developing novel therapeutic candidates as well as repurposing existing treatments for novel therapeutic purposes. Drug repurposing seeks to explore new uses for existing drugs and therapeutic candidates that already possess detailed pharmacology, formulat…
Bernard R Brooks · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2020 · $359,079 — Traditional molecular modeling is performed at atomic resolution, which relies on X-ray and NMR experiments to provide structural information. When dealing with biomolecular assemblies of millions of atoms, atomic description of molecular objects becomes very computational inefficient. We develope…
SUZETTE Alise PRIOLA · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $127,278 — Transmissible spongiform encephalopathies (TSEs or prion diseases) are a group of rare neurodegenerative diseases which include scrapie in sheep, bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD) in mule deer and elk. In humans, the most common type of prion disease is Creut…
Iain Fraser · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $883,554 — Innate immune cells constantly evaluate host mucosal surfaces and peripheral tissues for signs of infection or injury. The host must find a balance between tolerance of beneficial microorganisms and minor non-pathological microbial encounter vs. the development of a robust immune response to more se…
Robert Petrovich · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2020 · $1,751,612 — The protein expression facility (PEF) functions as a support group for the principle investigators at the NIEHS. Our focus is to provide the research groups with a means to generate the proteins they require so that they can perform their experiments. These projects range from generating enough o…
Andrea Marzi · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $94,907 — The lab developed 2 vaccine candidates expressing the SARS-CoV-2 spike protein alone or in combination with the Ebola virus glycoprotein (EBOV GP). Hamster studies revealed that a single dose of either vaccine administered intranasally or intramuscularly (IM) protected the animals from disease after…
Thomas Quinn · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $134,338 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged as a global pandemic in early 2020. By August of 2020, over 21 million cases of SARS-CoV-2 have been confirmed, spanning 188 countries and accounting for over have 750,0…
Timothy Cragin Wang · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2020 · $162,000 — PROJECT SUMMARY The SARS-CoV-2 pandemic has led to massive morbidity and mortality worldwide due to COVID-19, with the United States particularly affected. Risk factors for COVID-19 include male sex, older age, and obesity, amongst others, which are also key risk factors for Barrett’s esophagus (BE)…
OFER LEVY · BOSTON CHILDREN'S HOSPITAL · 2020 · $308,143 — LAS PROJECT SUMMARY: From a cluster of respiratory illnesses in Wuhan, China, to a worldwide pandemic, the world has learned of a novel coronavirus (SARS-CoV-2) but little is known about the pathogenesis that leads to the disease termed “COVID”. Patients with SARS-CoV-2 infection range from asymptom…
Kristina De Paris · DUKE UNIVERSITY · 2020 · $203,402 — ABSTRACT The emergence of the highly-transmissible novel coronavirus SARS-CoV-2 has led to a global pandemic of severe respiratory disease. While elderly individuals and adults with co-morbidities are high risk populations, coronavirus disease (COVID-19) can occur in individuals across all age group…
Lawrence A. Tabak · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · 2020 · $911,573 — Our lab studies the structure and function of GalNAc-Ts. in collaboration with Kelly Ten Hagen, NIH and Tom Gerkin, CWRU, we published a paper describing how the differential splicing of the lectin domain of a GalNAc-T modulates both peptide and glycopeptide preferences. We have also submitted a met…
JERREL L YAKEL · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2020 · $1,032,048 — The Viral Vector Core facility currently offers support for production, purification, titering, and validation of twelve types of viruses: Adenovirus, Adenoassociated virus (AAV), coronaviruses (229E, OC43, and NL63), Influenza A, lentiviruses including human immunodeficiency virus (HIV), Lymphocyti…
KENNETH Stephen KOSIK · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $296,067 — PROJECT SUMMARY/ABSTRACT — PROJECT 2 Many unknown pathogenic steps lie between normal tau protein in a healthy neuron and the cellular dysfunction that occurs as a result of tau uptake and aggregation. The aims address two emerging facets of the pathobiology: the mechanism of tau uptake in neur…
CHRISTOPHER PACK · METACLIPSE THERAPEUTICS CORPORATION · 2020 · $2,199,976 — Vaccine design using SARS-CoV-2 spike protein on VLPs which contain GM-CSF and IL-12 (targeting elderly). There is data supporting the premise that including GM-CSF and IL-12 in the VLP can overcome poor immune responses in elderly. Animal testing will begin using VLP with antigen and cytokines,…
JOHN ALTMAN · EMORY UNIVERSITY · 2020 · $400,000 — The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations. This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies. The TCF is producing MHC class I and class II tetram…
Bing Chen · BOSTON CHILDREN'S HOSPITAL · 2020 · $531,000 — Coronaviruses (CoVs) are enveloped positive-stranded RNA viruses that caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). To meet the urgent needs for diagnostics, therapeutics and vaccines to contain the current crisis, we need to gain deep…